1-(tert-butyl)-3-cyclopropylurea

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1-(tert-butyl)-3-cyclopropylurea
• 英文别名: 1-Tert-butyl-3-cyclopropylurea
• 化学式: C₈H₁₆N₂O
• mdl: MFCD14888550
• 分子量: 156.228
• InChiKey: VUWWEMMGEBUONK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  一氧化碳 、 1-(tert-butyl)-3-cyclopropylurea 在 [Rh(cod)2]BARF 、 三苯基膦 、 苯甲酸 作用下， 以 邻二氯苯 为溶剂， 90.0 ℃ 、101.33 kPa 条件下， 反应 48.0h， 生成 3-(tert-butyl)-1,3-diazepane-2,4-dione 、 1-(tert-butyl)-3,6-dihydro-1H-1,3-diazepine-2,7-dione
  参考文献：
  名称：

  Capture–Collapse Heterocyclization: 1,3-Diazepanes by C–N Reductive Elimination from Rhodacyclopentanones

  摘要：

  Rhodacydopentanones derived from carbonylative C-C activation of cyclopropyl ureas can be "captured" by pendant nucleophiles prior to "collapse" to 1,3-diazepanes. The choice of N-substituent on the cyclopropane unit controls the oxidation level of the product, such that C4-C5 unsaturated or saturated systems can be accessed selectively.

  DOI：

  10.1021/jacs.6b07046
• 作为产物：
  描述：

  环丙胺 、 叔丁基异氰酸酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以59%的产率得到1-(tert-butyl)-3-cyclopropylurea
  参考文献：
  名称：

  Capture–Collapse Heterocyclization: 1,3-Diazepanes by C–N Reductive Elimination from Rhodacyclopentanones

  摘要：

  Rhodacydopentanones derived from carbonylative C-C activation of cyclopropyl ureas can be "captured" by pendant nucleophiles prior to "collapse" to 1,3-diazepanes. The choice of N-substituent on the cyclopropane unit controls the oxidation level of the product, such that C4-C5 unsaturated or saturated systems can be accessed selectively.

  DOI：

  10.1021/jacs.6b07046

文献信息

• Inhibitors of Protein Tyrosine Kinase Activity
  申请人：Raeppel Stëphane

  公开号：US20110257100A1

  公开（公告）日：2011-10-20

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如，抑制VEGF受体信号传导。本发明还提供了用于治疗细胞增殖性疾病和条件以及眼科疾病、障碍和条件的化合物、组合物和方法。
• IL-17 Ligands And Uses Thereof
  申请人：DICE Molecules SV LLC.

  公开号：US20200247785A1

  公开（公告）日：2020-08-06

  Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.

  本文提供了新型配体及其药物组合物，可调节IL-17A。还提供了制备IL-17A调节剂的方法。这些化合物可能在治疗和/或预防炎症、癌症或自身免疫疾病等方面有用。
• Benzothiazole Kinase Inhibitors and Methods of Use
  申请人：Intellikine LLC

  公开号：US20150225407A1

  公开（公告）日：2015-08-13

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

  本发明提供了能够调节脂质激酶如PI3激酶、酪氨酸激酶和蛋白激酶如mTOR的化学实体或化合物以及其药物组合物。本发明还提供了使用这些组合物来调节这些激酶的方法，特别是用于治疗应用。
• INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
  申请人：Claridge Stephen William

  公开号：US20090264440A1

  公开（公告）日：2009-10-22

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，本发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号和HGF受体信号的传导。更具体地，本发明涉及抑制VEGF受体信号和HGF受体信号的化合物、组合物和方法。本发明还提供了治疗细胞增殖性疾病和状况的组合物和方法。
• BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS
  申请人：Bounaud Pierre-Yves

  公开号：US20090258855A1

  公开（公告）日：2009-10-15

  The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.

  本公开提供了双环三唑蛋白激酶调节剂以及使用这些化合物治疗由激酶活性介导的疾病的方法。